Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Assets (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Assets for 5 consecutive years, with $305.1 million as the latest value for Q1 2026.

  • For Q1 2026, Assets rose 3.71% year-over-year to $305.1 million; the TTM value through Mar 2026 reached $305.1 million, up 3.71%, while the annual FY2025 figure was $259.1 million, 31.5% down from the prior year.
  • Assets hit $305.1 million in Q1 2026 for Phathom Pharmaceuticals, up from $259.1 million in the prior quarter.
  • Across five years, Assets topped out at $413.8 million in Q4 2023 and bottomed at $144.0 million in Q1 2023.
  • Average Assets over 5 years is $269.4 million, with a median of $259.1 million recorded in 2025.
  • Year-over-year, Assets soared 151.1% in 2023 and then tumbled 37.92% in 2025.
  • Phathom Pharmaceuticals' Assets stood at $164.8 million in 2022, then skyrocketed by 151.1% to $413.8 million in 2023, then dropped by 8.58% to $378.3 million in 2024, then plummeted by 31.5% to $259.1 million in 2025, then increased by 17.74% to $305.1 million in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $305.1 million, $259.1 million, and $240.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.